.Attributes Medication, Published online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA research, after a median consequence of 11 months, people with metastatic stomach lumps that obtained biomarker-matched therapies based on circulating growth DNA profiling revealed a greater clinical advantage than those getting unequaled treatment.